A Phase 1/2 Multicenter, Randomized, Study to Evaluate the Safety and Efficacy of VS101 Subconjunctival Latanoprost Insert in Subjects With Open-Angle Glaucoma or Ocular Hypertension

NCT02129673 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

77

Enrollment

INDUSTRY

Sponsor class

Conditions

Open Angle Glaucoma
Ocular Hypertension

Interventions

DRUG: VS101 Insert Dose A
DRUG: VS101 Insert Dose B
DRUG: VS101 Insert Dose C
DRUG: Latanoprost 0.005% eye drops

Sponsor

ViSci Ltd.